Casi Pharmaceuticals (CASI)

[Mirdad]

I really don't understand what all the excitement is with this company? The latest presentation by CASI management state all 3 combined drugs will provide peak annual sales of only $148M. The closest drug to actually being sold is Evomela and that isn't until Q4 2019 and will provide peak sales of only $35M. While this is all good news it does not translate into a lot of revenue to greatly propel the share price. I admit I'm new to the stock so I'm no expert here. I really like the idea of them using their contacts within China to not only sell product but also provide low cost manufacturing but the total peak revenues are nothing to write home about. What am I missing here? Perhaps this is more of a very long term hold as I like their strategy of being the next Celgene in China........but they have a long long way to go...... Maybe this is more of a ten year hold as I don't see enough in the pipeline to generate at least $500M to $1B in annual peak sales......at least not according to their own presentation. It is encouraging to see large insider buys;this adds to my conundrum regarding investing strongly in the company.

I appreciate if anyone can shed any light on the aforementioned issues I have stated. Perhaps I messed up on some points of data?